Skip to main content
. 2019 Jun 5;33(6):448–454. doi: 10.1089/end.2019.0067

Table 4.

Subset Analysis of Benign Prostatic Hyperplasia Treatment Modalities and Risk of Device Malfunction

  MAUDE I MAUDE II–IV Odds ratio CI p
TURP 188 9 0.457 0.169–1.384 0.319
HoLEP 34 5 1.27 0.378–4.142 0.722
UroLift® 14 2 2.26 0.526–8.480 0.269
Total 236 16 — — —